FY2025 EPS Estimates for Opthea Reduced by Leerink Partnrs

Opthea Limited (NASDAQ:OPT) – Analysts at Leerink Partnrs decreased their FY2025 earnings estimates for shares of Opthea in a report issued on Monday, March 24th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings per share of ($1.62) for the year, down from their previous estimate of ($1.15). Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Opthea’s current full-year earnings is ($1.39) per share. Leerink Partnrs also issued estimates for Opthea’s FY2026 earnings at ($0.36) EPS, FY2027 earnings at ($0.41) EPS and FY2028 earnings at ($0.37) EPS.

A number of other equities research analysts also recently commented on the company. Jefferies Financial Group reiterated an “underperform” rating and set a $1.00 price objective (down previously from $8.00) on shares of Opthea in a research report on Tuesday. HC Wainwright cut Opthea from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $12.00 to $2.00 in a research note on Tuesday. Leerink Partners lowered shares of Opthea from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $12.00 to $1.00 in a research note on Tuesday. Oppenheimer downgraded Opthea from an “outperform” rating to a “market perform” rating in a report on Monday. Finally, Canaccord Genuity Group raised Opthea to a “strong-buy” rating in a research note on Tuesday, December 17th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $1.33.

Opthea Stock Performance

Shares of NASDAQ:OPT opened at $3.41 on Thursday. Opthea has a 1-year low of $1.79 and a 1-year high of $6.30. The company has a 50 day moving average price of $4.41 and a 200 day moving average price of $4.06.

Institutional Trading of Opthea

A number of institutional investors have recently bought and sold shares of the company. Jane Street Group LLC acquired a new position in Opthea in the 3rd quarter worth about $114,000. Twin Lakes Capital Management LLC bought a new stake in shares of Opthea in the 3rd quarter valued at approximately $81,000. ABC Arbitrage SA acquired a new position in Opthea in the fourth quarter worth approximately $40,000. OLD Mission Capital LLC bought a new position in Opthea during the fourth quarter valued at approximately $42,000. Finally, Hsbc Holdings PLC acquired a new stake in Opthea in the fourth quarter valued at approximately $556,000. Institutional investors and hedge funds own 55.95% of the company’s stock.

Opthea Company Profile

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.